Blockchain Registration Transaction Record

LataMed AI Updates on Forward Stock Split and AI Platform Progress

LataMed AI Corp. provides update on 5-for-1 forward stock split and mandatory share exchange. FINRA review expected within a week. New CUSIP 21116R404. CEO highlights progress on CardioAI, PulmoAI, NeuroAI platforms.

This news matters because it directly affects shareholders of LataMed AI Corp. The forward stock split and mandatory share exchange are significant corporate actions that will alter the number of shares held and the CUSIP number. Understanding the process is crucial for shareholders, especially those with physical certificates, to ensure they receive the correct post-split shares. Additionally, the company's focus on advancing its AI platforms—CardioAI, PulmoAI, and NeuroAI—highlights its commitment to building a digital healthcare ecosystem in Latin America, which could improve healthcare access in underserved regions. For investors, this update signals the company's progress toward its strategic goals and provides clarity on the mechanics of the stock split.